Person-years | VTE | Incidence rate (95% CI)# | HR (95% CI)¶ | HR (95% CI)+ | |
All VTE | |||||
Normal | 41 744 | 137 | 3.3 (2.8–3.9) | 1 (reference) | 1 (reference) |
Stage I | 5912 | 26 | 4.4 (3.0–6.3) | 0.98 (0.64–1.50) | 1.02 (0.66–1.57) |
Stage II | 8008 | 40 | 5.0 (3.7–6.8) | 1.09 (0.76–1.56) | 1.12 (0.78–1.62) |
Stage III/IV | 1526 | 12 | 7.9 (4.5–13.8) | 1.61 (0.90–2.93) | 1.60 (0.88–2.92) |
p-value for trend | 0.2 | 0.2 | |||
Unprovoked VTE | |||||
Normal | 41 744 | 55 | 1.3 (1.0–1.7) | 1 (reference) | 1 (reference) |
Stage I | 5912 | 6 | 1.0 (0.5–2.3) | 0.55 (0.24–1.29) | 0.62 (0.26–1.46) |
Stage II | 8008 | 15 | 1.9 (1.1–3.1) | 1.00 (0.56–1.78) | 1.07 (0.59–1.95) |
Stage III/IV | 1526 | 3 | 2.0 (0.6–6.1) | 0.99 (0.31–3.25) | 1.04 (0.32–3.39) |
p-value for trend | 0.8 | 1.0 | |||
Secondary VTE | |||||
Normal | 41 744 | 82 | 2.0 (1.6–2.4) | 1 (reference) | 1 (reference) |
Stage I | 5912 | 20 | 3.4 (2.2–5.2) | 1.28 (0.78–2.10) | 1.27 (0.76–2.12) |
Stage II | 8008 | 25 | 3.1 (2.1–4.6) | 1.16 (0.73–1.82) | 1.14 (0.72–1.83) |
Stage III/IV | 1526 | 9 | 5.9 (3.1–11.3) | 2.05 (1.02–4.10) | 1.97 (0.97–3.99) |
p-value for trend | 0.1 | 0.1 | |||
Provoked VTE | |||||
Normal | 41 744 | 39 | 0.9 (0.7–1.3) | 1 (reference) | 1 (reference) |
Stage I | 5912 | 12 | 2.0 (1.0–3.4) | 1.39 (0.71–2.74) | 1.53 (0.76–3.06) |
Stage II | 8008 | 14 | 1.7 (1.0–3.0) | 1.27 (0.68–2.35) | 1.25 (0.66–2.37) |
Stage III/IV | 1526 | 4 | 2.6 (1.0–7.0) | 1.77 (0.63–5.00) | 1.71 (0.60–4.88) |
p-value for trend | 0.2 | 0.3 | |||
Cancer-related VTE | |||||
Normal | 41 744 | 43 | 1.0 (0.8–1.4) | 1 (reference) | 1 (reference) |
Stage I | 5912 | 8 | 1.4 (0.7–2.7) | 1.05 (0.49–2.25) | 1.04 (0.49–2.25) |
Stage II | 8008 | 11 | 1.4 (0.8–2.5) | 1.03 (0.53–2.03) | 1.04 (0.52–2.07) |
Stage III/IV | 1526 | 5 | 3.3 (1.4–7.9) | 2.33 (0.91–5.95) | 2.28 (0.88–5.91) |
p-value for trend | 0.3 | 0.3 | |||
PE | |||||
Normal | 41 744 | 68 | 1.6 (1.3–2.1) | 1 (reference) | 1 (reference) |
Stage I | 5912 | 15 | 2.5 (1.5–4.2) | 1.12 (0.64–1.96) | 1.21 (0.68–2.14) |
Stage II | 8008 | 19 | 2.4 (1.5–3.7) | 1.01 (0.60–1.69) | 1.01 (0.60–1.72) |
Stage III/IV | 1526 | 7 | 4.6 (2.2–9.6) | 1.83 (0.83–4.02) | 1.80 (0.81–3.99) |
p-value for trend | 0.4 | 0.4 | |||
DVT | |||||
Normal | 41 744 | 69 | 1.7 (1.3–2.1) | 1 (reference) | 1 (reference) |
Stage I | 5912 | 11 | 1.9 (1.0–3.4) | 0.84 (0.44–1.60) | 0.82 (0.41–1.61) |
Stage II | 8008 | 21 | 2.6 (1.7–4.0) | 1.18 (0.72–1.93) | 1.22 (0.73–2.04) |
Stage III/IV | 1526 | 5 | 3.3 (1.4–7.9) | 1.38 (0.55–3.45) | 1.39 (0.55–3.51) |
p-value for trend | 0.5 | 0.4 |
Data are presented as n, unless otherwise stated. PE: pulmonary embolism; DVT: deep vein thrombosis. #: per 1000 person-years; ¶: age was timescale; adjusted for sex; +: adjusted for age, sex, current smoking, body mass index and self-reported cardiovascular diseases (myocardial infarction, angina or stroke).